Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials ( r immediate release formulation of NG2-...)

Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials

r immediate release formulation of NG2-73 Different sustained formulations are designated as "A" or "B"

Safety Profile

In both studies, NG2-73 was safe and well tolerated at all doses tested. One drug-related SAE was observed. The favorable safety and tolerability profile of NG2-73 observed in studies 202 and 203 was consistent with that observed in previous studies. NG2-73 has now been tested in more than 600 subjects.

Secondary Endpoints

Both studies included several secondary (exploratory) endpoints to obtain additional data on sleep onset, sleep maintenance and potential side-effects. These measures included LPS, WASO, Total Sleep Time (TST), Sleep Efficiency (SE), Wake Time During Sleep (WTDS), Digit Symbol Substitution Test (DSST) and Visual Analog Scales (VAS) on sedation. With regard to secondary endpoints, data from Study 202 - the sleep maintenance study -- were internally consistent and statistically significant with respect to sleep onset and maintenance. In this study, the controlled release formulation using matrix "A" described above generally performed best on all parameters with no next-day residual sedation effects. In study 203--the sleep onset study - sleep maintenance, as measured by the secondary endpoints described above, was not observed. In both studies, as expected, residual effects as measured by DSST, were observed in higher doses and with formulations with more prolonged release profiles.

Webcast

Neurogen will host a conference call and webcast to discuss this announcement at 8:30 ET today. The webcast will be available in the Investor Relations section of www.neurogen.com and will also be archived there. A replay of the call will be available after 1:00 pm ET today and accessible through the close of business, July 9, 2007. To replay the conference call, dial 888-286-8010, or for international callers, 617-801-6888, and use the pass code: 95330673.

About Neurogen's Insomnia Program'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:

(Date:5/21/2013)... 21, 2013 The North Shore-LIJ Health System is ... hand-washing compliance at North Shore University Hospital in ... operating rooms at Forest Hills ... The new pilot program strengthens patient safety by ... (ORs), the first time in the US that remote ...

(Date:5/21/2013)... May 21, 2013 Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...

(Date:5/21/2013)... ST. LOUIS , May 21, 2013 ... to treat chronic, complex diseases such as cancer, multiple ... 67 percent by the end of 2015, according to ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) ... time for employers and health plans to act so ...

Breaking Medicine Technology:North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2 North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3 North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5

[0] North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs [0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015

... Maine, Jan. 11 IDEXX Laboratories, Inc. (Nasdaq: ... of 2,000 Catalyst Dx® chemistry analyzers in 2009, bringing ... in the first quarter of 2008, is a next ... integrated suite of analyzers and significantly expands the range ...

... , SAN DIEGO, Jan 11 Volcano Corporation (Nasdaq: ... of products for the diagnosis and treatment of coronary and ... for fiscal 2009 will be approximately $228.0 million, with revenues ... approximately $71.0 million. , The revenue expectations for fiscal 2009 ...

Cached Medicine Technology:IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers 2 Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance 2 Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance 3 Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance 4

IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance

(Date:5/21/2013)... drugs which lower intraocular pressure, are often the first ... use is not without risks. PGAs have long been ... and other side effects. Now a new study has ... eyelid drooping and other issues that can interfere with ... . , Researchers from the Massachusetts Eye and Ear ...

(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...

(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...

(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...

(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...

Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2 Health News:New Talent Joins the HealthSmart Account Management Team 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4 Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2

[0] Glaucoma drug can cause droopy eyelids [0] New Talent Joins the HealthSmart Account Management Team [0] ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships

... SAN ANTONIO, July 15 While some say that paying ... of Starbuck,s coffee is expensive, there,are many who are willing ... sales jumped 13% to $315.5 million. With Botox sales on ... economic recession or has,looking good become a necessity?, A ...

... Althea Technologies, Inc., a leading,provider of innovative ... announced today that E.J. Brandreth has,joined the ... Regulatory. In this,role, Mr. Brandreth will be ... while overseeing the regulatory support activities,which are ...

... and financial resources, including Social Security Disability Insurance benefits, when individuals ... ... IL (Vocus) July 15, 2008 -- Someone can become disabled in ... a gradual onset of chronic illness. Then the financial blow hits—the ...

... Straight teeth can improve your dental health, enhance your facial appearance and ... a huge difference in the quality of one's life. Both children and ... Orthodontic treatment can benefit social and career success as well as improve ... ...

... social and economic resources were more supportive in ... which in turn influenced the children,s cognitive performance. ... that considers how economic factors and parenting quality ... the Center for Research on Culture, Development, and ...

... A new vision screening device, already shown to give ... patients a head start on treating diabetes and its vision ... by two scientists at the University of Michigan Kellogg Eye ... and tissue damage that occur before the first symptoms of ...

Cached Medicine News:Health News:Kimberly Finder, M.D. Asks: Are We Really In an Economic Recession? 2 Health News:Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory 2 Health News:Key Steps Can Help with Financial Impact of Disability 2 Health News:Key Steps Can Help with Financial Impact of Disability 3 Health News:Key Steps Can Help with Financial Impact of Disability 4 Health News:Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment 2 Health News:Family resources, parenting quality influence children's early cognitive development 2 Health News:'Snapshots' of eyes could serve as early warning of diabetes 2 Health News:'Snapshots' of eyes could serve as early warning of diabetes 3

Kimberly Finder, M.D. Asks: Are We Really In an Economic Recession?Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory Key Steps Can Help with Financial Impact of Disability Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment Family resources, parenting quality influence children's early cognitive development 'Snapshots' of eyes could serve as early warning of diabetes

Single-Piece PMMA Intraocular Lenses....

Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....

Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....

STABIBAG Hydrophilic Acrylic Lens....

Medicine Products:

Single-Piece Intraocular Lens with haptic eyelets Single Piece PMMA Lens (Refractive and Bifocal)NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal)STABIBAG Hydrophilic Acrylic Lens